VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 8, 2008) - Allon Therapeutics Inc. (TSX:NPC) presented today at the BIO-Europe Spring 2008 partnership conference in Madrid, Spain, sharing with prospective pharmaceutical partners the human efficacy data from the Company's Phase IIa clinical trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD).
